Chemotherapeutics of visceral leishmaniasis: present and future developments.
Parasitology
; 145(4): 481-489, 2018 04.
Article
en En
| MEDLINE
| ID: mdl-29215329
ABSTRACT
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Leishmania donovani
/
Resultado del Tratamiento
/
Leishmaniasis Visceral
/
Antiprotozoarios
Límite:
Animals
/
Humans
País/Región como asunto:
America do sul
/
Asia
Idioma:
En
Revista:
Parasitology
Año:
2018
Tipo del documento:
Article
País de afiliación:
India